Nu Skin (NUS) Q3 2026 Earnings Call Transcript
Nu Skin (NUS) reported Q3 2026 revenue of $311M, with adjusted EPS of $0.10. The company highlighted a 10% scan-to-purchase conversion rate and 3% year-to-date sales growth for LifePak. Nu Skin plans to launch innovations in anti-aging and women's health mid-2027 and is preparing for India's market entry in early 2027. The company is restructuring to improve efficiency and profitability, with a focus on East-West market alignment.
How this was made
The 30-second read
Why it matters
The earnings release introduces new financial metrics and forward guidance, offering traders fresh data to reassess valuation.
Market read
First‑time earnings disclosure with modest miss on margins; actionable for short‑term positioning.
What to watch
Improved scan‑to‑purchase conversion and upcoming India market entry may drive longer‑term growth.
Background
Nu Skin Enterprises reported Q3 2026 results, highlighting a revenue range within guidance, margin compression, and a strategic focus on AI‑enabled app, India launch, and cost efficiencies.
Ticker impact
Q3 2026 earnings released with revenue $311M, EPS -$0.02, margin decline and guidance for Q4.
potential downside as investors price in weaker gross margin and modest outlook
The transcript provides first‑time disclosure of quarterly results and forward guidance, which are material for pricing.
Market effects
Wellness and direct‑selling sector may see scrutiny on margin pressures.
North American investors may adjust exposure to multi‑level marketing firms.
Limited; impact confined to Nu Skin and peers in the personal‑care segment.
Counterpoint
If the company can sustain its new AI‑driven app and India launch, the short‑term dip could be over‑reacted.
Key entities
- companyNu Skin Enterprises
US‑listed personal‑care and wellness company (ticker NUS).
